Journal Article
Randomized Controlled Trial
Add like
Add dislike
Add to saved papers

[Open prospective randomized study of the results of using Venarus in postthrombotic disease].

Presented herein are the outcomes of conservative treatment of patients suffering from post-thrombotic disease and chronic venous insufficiency of the lower extremities. Our open prospective randomized study included a total of eighty patients divided into two groups, each consisting of 40 people. All patients were subjected to standard comprehensive conservative treatment, with Group Two patients additionally prescribed Venarus. Efficacy of treatment for post-thrombotic disease was assessed with the use of the Villalta scale. The obtained findings demonstrated clinically significant improvement of the main clinical symptoms in Group Two patients, thus suggesting efficacy of the drug as soon as after a short period of administration. Treatment with Venarus in patients with distal forms of involvement of deep veins of the lower limbs was accompanied and followed by improvement of the tonicoelastic properties of the intact common femoral vein. Healing of small trophic ulcers was conditioned by efficacy of the drug at the level of the microcirculatory bed.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app